AIMS. To compare trends in diagnoses, monitoring and mortality in patients with type 2 diabetes, before and after the first COVID-19 peak. METHODS. We constructed a cohort of 25 million patients using electronic health records from 1831 UK general practices registered with the Clinical Practice Research Datalink (CPRD), including 14 million patients followed between March and December 2020. We compared trends using regression models and 10-year historical data. We extrapolated the number of missed/delayed diagnoses using UK Office for National Statistics data. RESULTS. In England, rates of new type 2 diabetes diagnoses were reduced by 70% (95% CI 68%-71%) in April 2020, with similar reductions in Northern Ireland, Scotland and Wales. Between March and December, we estimate that there were approximately 60,000 missed/delayed diagnoses across the UK. In April, rates of HbA1c testing were greatly reduced in England (reduction: 77% (95% CI 76%-78%)) with more marked reductions in the other UK nations (83% (83-84%)). Reduced rates of diagnosing and monitoring were particularly evident in older people, in males, and in those from deprived areas. In April, the mortality rate in England was more than 2-fold higher (112%) compared to prior trends, but was only 65% higher in Northern Ireland, Scotland and Wales. CONCLUSIONS. As engagement increases, healthcare services will need to manage the backlog and anticipate greater deterioration of glucose control due to delayed diagnoses and reduced monitoring in those with pre-existing diabetes. Older people, men, and those from deprived backgrounds will be groups to target for early intervention.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) plays critical roles in host cell entry. Non-synonymous substitutions affecting S are not uncommon and have become fixed in a number of SARS-CoV-2 lineages. A subset of such mutations enable escape from neutralizing antibodies or are thought to enhance transmission through mechanisms such as increased affinity for the cell entry receptor, angiotensin-converting enzyme 2 (ACE2). Independent genomic surveillance programs based in New Mexico and Louisiana contemporaneously detected the rapid rise of numerous clade 20G (lineage B.1.2) infections carrying a Q677P substitution in S. The variant was first detected in the US on October 23, yet between 01 Dec 2020 and 19 Jan 2021 it rose to represent 27.8% and 11.3% of all SARS-CoV-2 genomes sequenced from Louisiana and New Mexico, respectively. Q677P cases have been detected predominantly in the south central and southwest United States; as of 03 Feb 2021, GISAID data show 499 viral sequences of this variant from the USA. Phylogenetic analyses revealed the independent evolution and spread of at least six distinct Q677H sub-lineages, with first collection dates ranging from mid-August to late November 2020. Four 677H clades from clade 20G (B.1.2), 20A (B.1.234), and 20B (B.1.1.220, and B.1.1.222) each contain roughly 100 or fewer sequenced cases, while a distinct pair of clade 20G clusters are represented by 754 and 298 cases, respectively. Although sampling bias and founder effects may have contributed to the rise of S:677 polymorphic variants, the proximity of this position to the polybasic cleavage site at the S1/S2 boundary are consistent with its potential functional relevance during cell entry, suggesting parallel evolution of a trait that may confer an advantage in spread or transmission. Taken together, our findings demonstrate simultaneous convergent evolution, thus providing an impetus to further evaluate S:677 polymorphisms for effects on proteolytic processing, cell tropism, and transmissibility.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) plays critical roles in host cell entry. Non-synonymous substitutions affecting S are not uncommon and have become fixed in a number of SARS-CoV-2 lineages. A subset of such mutations enable escape from neutralizing antibodies or are thought to enhance transmission through mechanisms such as increased affinity for the cell entry receptor, ACE2. Independent genomic surveillance programs based in New Mexico and Louisiana contemporaneously detected the rapid rise of numerous clade 20G (lineage B.1.2) infections carrying a Q677P substitution in S. The variant was first detected in the US on October 23, yet between 01 Dec 2020 and 19 Jan 2021 it rose to represent 27.8% and 11.3% of all SARS-CoV-2 genomes sequenced from Louisiana and New Mexico, respectively. Q677P cases have been detected predominantly in the south central and southwest United States; as of 03 Feb 2021, GISAID data show 499 viral sequences of this variant from the USA. Phylogenetic analyses revealed the independent evolution and spread of at least six distinct Q677H sub-lineages, with first collection dates ranging from mid August to late November, 2020. Four 677H clades from clade 20G (B.1.2) , 20A (B.1.234), and 20B (B.1.1.220, and B.1.1.222) each contain roughly 100 or fewer sequenced cases, while a distinct pair of clade 20G clusters are represented by 754 and 298 cases, respectively. Although sampling bias and founder effects may have contributed to the rise of S:677 polymorphic variants, the proximity of this position to the polybasic cleavage site at the S1/S2 boundary are consistent with its potential functional relevance during cell entry, suggesting parallel evolution of a trait that may confer an advantage in spread or transmission. Taken together, our findings demonstrate simultaneous convergent evolution, thus providing an impetus to further evaluate S:677 polymorphisms for effects on proteolytic processing, cell tropism, and transmissibility.
Objective Many anecdotal reports indicate the presence of ′long COVID′ - COVID-19-related symptoms weeks to months after the acute illness. However, frequency and symptom-pattern of ′long COVID′ in relation to acute disease severity are uncertain. As part of an ongoing, prospective cohort study we therefore conducted an online survey among adults 6 months after acute COVID-19. Methods The prospective online study Life&Covid is ongoing in Germany since May 2020. Participants were recruited 0 to 4 months after their SARS-CoV-2 infection und followed up by subsequent surveys. The survey 6 months after the infection was completed by 127 out of 148 individuals invited by email (86%). All grades of acute disease severity were included and 91% of the participants had been treated as outpatients during their acute illness. Results Six months after the infection, 67% of the study participants reported at least one symptom as a consequence of COVID-19. Exertional dyspnea (30% of participants), fatigue (25%) and diminished sense of taste/smell (19%) were the most common individual symptoms. At least one symptom, exertional dyspnea, and fatigue were reported more often after a severe acute illness, but diminished sense of taste/smell was unrelated to acute severity. Age group and sex did not associate with the frequency of symptoms at 6 months. Conclusions Based on this study, the prevalence of COVID-19-related symptoms 6 months after the infection is high. Some bias for overestimation may have affected this result. Nevertheless, ′long COVID′ requires attention in medical care and a better scientific understanding.
Introduction- Severe Acute Respiratory Syndrome Corona virus-2 (SARS-CoV-2) spread mainly through respiratory droplets and contact routes. Long term use of spectacles may prevent repeated touching and rubbing of the eyes. Aim of the study is to compare the risk of COVID-19 in long term spectacles wearers with the risk in persons not using spectacles. Objectives- To know the association between infection with SARSCoV-2 and wearing of spectacles. Materials and methods- In this study, 304 patients of Corona virus disease 2019 (COVID-19) were selected. Their spectacles wearing behaviour was assessed through a questionnaire. Spectacles wearing behaviour of general population was obtained from older studies (for comparison). Risk of COVID-19 was calculated in long term spectacles wearers as well as in persons not using spectacles. Chi- Square test was used for statistical analysis. Results- In this study, total 58 patients showed the behavior of using spectacles continuously during day time and always on outdoor activities. The risk of COVID-19 was found 0.48 in spectacles wearing population as compared to 1.35 in population not using spectacles. The calculated risk ratio was 0.36. The protective effectiveness of the spectacles was found statistically significant (p- value .00113). Conclusion- The present study showed that the risk of Covid-19 was about 2- 3 times less in spectacles wearing population than the population not wearing those. The nasolacrimal duct may be a route of virus transmission from conjunctival sac to the nasopharynx.
Screening, testing and contact tracing plays a pivotal role in the control of COVID-19 pandemic. To carry out this strategy it is necessary to increase the testing capacity. Here, we compared a SARS CoV-2 rapid antigen test (RAT) and RT-PCR in 842 asymptomatic individuals from Tarapaca, Chile. We report a sensibility of 69.86%, a specificity of 99.61%, PPV of 94.44% and NPP of 97.22% with Ct values (Ct > 27) that were significantly higher among individuals with false-negative RAT. These results support the fact that RAT might have a significant impact in the identification of asymptomatic carriers in areas that lack well-equipped laboratories to perform SARS-CoV-2 real -time RT-PCR diagnostics or the results take more than 24-48 hours, as well as zones with high traffic of individuals, such as border/customs, airports, interregional bus, train stations or in any mass testing campaign requiring rapid results.
Public policy and academic debates regarding mitigation strategies frequently note potential disease-economy trade-offs, and advocate for prioritizing one outcome over the other. Using a calibrated coupled epi-economic model of individual behavior embedded within the broader economy during COVID-19, we show that targeted isolation strategies can avert up to 91% of individual economic losses relative to voluntary isolation strategies. Notably, the economic savings from targeted isolation strategies do not impose an additional disease burden, avoiding disease-economy trade-offs. In contrast, widely-used blanket lockdowns do create sharp disease-economy trade-offs and impose substantial economic costs per marginal case avoided. These results highlight the benefits of targeted isolation strategies for disease control, as they address the fundamental coordination failure between infectious and susceptible individuals which drives the recession. Our coupled-systems framework uses a novel data-driven approach to map economic activities to contacts, which facilitates developing effective mitigation strategies for future novel pathogens. Application of this framework can help control disease spread and avert trillions of dollars in losses.
Wastewater-based epidemiology could be applied to track down SARS-CoV-2 outbreaks at high spatio-temporal resolution and could potentially be used as an early-warning for emergence of SARS-CoV-2 circulation in the general population. Epidemiological surveillance of SARS-CoV-2 could play a role in monitoring the spread of the virus in the population and controlling possible outbreaks. However, sensitive sample preparation and detection methods are necessary to detect trace levels of SARS-CoV-2 RNA in influent wastewater (IWW). Unlike predecessors, method development of a SARS-CoV-2 RNA concentration and detection procedure was performed with IWW samples with high viral SARS-CoV-2 loads (in combination with seeding IWW with a surrogate coronavirus). This is of importance since the SARS-CoV-2 genome in IWW might have already been subject to in-sewer degradation into smaller genome fragments or might be present in a different form (e.g. cell debris,etc). Centricon Plus-70 (100 kDa) centrifugal filter devices resulted in the lowest and most reproducible Ct-values for SARS-CoV-2 RNA. Lowering pore sizes did not improve our limit of detection and quantification. Real-time polymerase chain reaction (qPCR) was employed for the amplification of the N1, N2, N3 and E_Sarbeco-gene. This is one of the first studies to apply digital polymerase chain reaction (dPCR) for the detection of SARS-CoV-2 RNA in IWW. Interestingly, qPCR results were comparable with dPCR results suggesting that qPCR is a valid method. In this study, dPCR was also used as a proxy to assess the precision of qPCR. In this light, dPCR showed high variability at low concentration levels (100 copies/microliter), indicating that variability in bioanalytical assays for SARS-CoV-2 RNA might be substantial. On average, the N2-gene showed high in-sample stability in IWW for 10 days of storage at 4 degrees. Between-sample variability was substantial due to the low native concentrations in IWW. Additionally, the E-gene proved to be less stable compared to the N2-gene and showed higher variability. Freezing the IWW samples resulted in a 10-fold decay of loads of the N2- and E-gene in IWW. Although WBE can already aid in filling some knowledge gaps in the epidemiological surveillance of SARS-CoV-2, future WBE studies should aim to further validate and standardize bioanalytical assays, especially with regards to methodological limitations.
Background: India bears the second largest burden of SARS-CoV-2 infection. A multitude of RT-PCR detection assays with disparate gene targets including automated high throughput platforms are available. Varying concordance and interpretation of diagnostic results in this setting can result in significant reporting delays leading to suboptimal disease management. Here, we report the development of a novel ORF-1a based SARS-CoV-2 RT-PCR assay, Viroselect, showing high concordance with conventional assays and the ability to resolve inconclusive results generated during the peak of the epidemic in Mumbai, India. Methods: We identified a unique target region within SARS-CoV-2 ORF1a, non-structural protein (nsp3), that was used to design and develop our assay. This hypervariable region (1933-3956) between SARS-CoV-2, SARS-CoV, and MERS-COV was utilized to design our primers and probe for RT-PCR assay. We further evaluated concordance of our assay with commonly used EUA (USFDA) manual kits as well as an automated high throughput testing platform. Further, a retrospective analysis using Viroselect on samples reported as inconclusive during April-October 2020 was carried out. Results: A total of 701 samples were tested. Concordance analysis of 477 samples demonstrated high overall agreement of Viroselect assay with both manual (87.6%; 95% CI) as well as automated (84.7%; 95% CI) testing assays. Also, in the retrospective analysis of 224 additional samples reported as inconclusive, Viroselect was able to resolve 100% (19/19) and 93.7% (192/205) samples which were termed inconclusive by manual and automated high throughput platform respectively. Conclusion: We show that Viroselect had high concordance with conventional assays, both manual and automated, as well as highlight its potential in resolving inconclusive samples.
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 - Condition: Severe COVID-19
Interventions: Drug: VB-201 + Standard of care; Drug: Standard of care
Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting
Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia - Condition: COVID-19
Intervention: Drug: Tofacitinib
Sponsor: I.M. Sechenov First Moscow State Medical University
Completed
Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19 - Condition: COVID-19
Interventions: Dietary Supplement: Nicotinamide; Dietary Supplement: Placebo
Sponsor: University Hospital Schleswig-Holstein
Recruiting
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19) - Condition: COVID-19
Interventions: Drug: Remdesivir; Drug: RDV Placebo; Drug: Standard of Care
Sponsor: Gilead Sciences
Not yet recruiting
COVID-19 Convalescent Plasma Therapy - Conditions: SARS-CoV-2 Infection; COVID-19 Infection
Intervention: Biological: Convalescent plasma
Sponsors: Angelica Samudio; Consejo Nacional de Ciencias y Tecnología, Paraguay; Ministerio de Salud Pública y Bienestar Social, Paraguay; Centro de información y recursos para el desarrollo, Paraguay
Completed
A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19) - Condition: Coronavirus Disease 2019 (COVID-19)
Interventions: Drug: Placebo; Drug: Prothione™ (6g)
Sponsor: Prothione, LLC
Not yet recruiting
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 - Conditions: Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19
Interventions: Drug: SNG001; Drug: Placebo
Sponsor: Synairgen Research Ltd.
Recruiting
Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19 - Condition: Covid19
Interventions: Biological: COVI-AMG; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms - Condition: Covid19
Interventions: Biological: COVI-AMG; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
An Effectiveness Study of the Sinovac’s Adsorbed COVID-19 (Inactivated) Vaccine - Condition: Covid19
Intervention: Biological: Adsorbed COVID-19 (Inactivated) Vaccine
Sponsor: Butantan Institute
Enrolling by invitation
Telerehabilitation in Covid-19 After Hospital Discharge - Condition: Covid19
Interventions: Other: Standard Physiotherapy program; Other: Telerehabilitation
Sponsor: Universidad de Granada
Not yet recruiting
Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection - Conditions: Covid19; SARS-CoV 2
Intervention: Other: Sampling by venipuncture
Sponsor: Centre Hospitalier Régional d’Orléans
Recruiting
Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19 - Condition: Covid19
Intervention: Other: prone position
Sponsor: Southeast University, China
Not yet recruiting
Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines - Condition: Covid-19 Vaccine
Intervention: Biological: CoronoVac Vaccine
Sponsors: Izmir Bakircay University; Cigli Regional Training Hospital; Muğla Sıtkı Koçman University
Not yet recruiting
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients - Condition: Covid-19
Interventions: Drug: CPI-006 2 mg/kg + SOC; Drug: CPI-006 1 mg/kg + SOC; Drug: Placebo + SOC
Sponsor: Corvus Pharmaceuticals, Inc.
Recruiting
Network Meta-analysis on the Mechanisms Underlying Alcohol Augmentation of COVID-19 Pathologies - CONCLUSIONS: Our meta-analyses demonstrate that EtOH exposure may augment SARS-CoV-2-induced inflammation by altering the activity of key inflammatory mediators. Medical records of COVID-19 patients are sparse for drinking history. Our findings suggest the importance to caution against alcohol consumption, which has increased during the COVID-19 pandemic, and facilitate further investigation into how alcohol exposure may affect viral infections.
A Developmental Pathway From Early Behavioral Inhibition to Young Adults’ Anxiety During the COVID-19 Pandemic - CONCLUSION: This study identifies a developmental pathway from toddlerhood BI to young adults’ elevated anxiety during the COVID-19 pandemic. Findings have implications for early identification of individuals at risk for dysregulated worry and the prevention of anxiety during stressful life events in young adulthood.
Three Salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2 - Since December 2019, the new coronavirus [also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, 2019-nCoV)]- induced disease, COVID-19, has spread rapidly worldwide. Studies have reported that the traditional Chinese medicine Salvia miltiorrhiza possesses remarkable antiviral properties; however, the anti-coronaviral activity of its main components, salvianolic acid A (SAA), salvianolic acid B (SAB), and salvianolic acid C (SAC) is still debated. In this study, we used Cell…
Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications - The coronavirus disease 2019 (COVID-19) pandemic is caused by a novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2). Here, we review the molecular pathogenesis of SARS-CoV-2 and its relationship with oxidative stress (OS) and inflammation. Furthermore, we analyze the potential role of antioxidant and anti-inflammatory therapies to prevent severe complications. OS has a potential key role in the COVID-19 pathogenesis by triggering the NOD-like receptor family pyrin domain…
Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors - Currently, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected people among all countries and is a pandemic as declared by the World Health Organization (WHO). SARS-CoVID-2 main protease is one of the therapeutic drug targets that has been shown to reduce virus replication, and its high-resolution 3D structures in complex with inhibitors have been solved. Previously, we had demonstrated the potential of natural compounds such as serine protease inhibitors eventually leading…
Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand - CONCLUSION: The sVNT is a practical and robust serological test for SARS-CoV-2 infection and does not require specialized biosafety containment. It can be used clinically to aid diagnosis in both early and late infection especially in cases when the real-time RT-PCR results in weakly negative or weakly positive, and to determine the protective immune response from SARS-CoV-2 infection in patients.
Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19 - In the search for inhibitors of COVID-19, we have targeted the interaction between the human angiotensin-converting enzyme 2 (ACE2) receptor and the spike receptor binding domain (S1-RBD) of SARS-CoV-2. Virtual screening of a library of natural compounds identified Kobophenol A as a potential inhibitor. Kobophenol A was then found to block the interaction between the ACE2 receptor and S1-RBD in vitro with an IC(50) of 1.81 ± 0.04 μM and inhibit SARS-CoV-2 viral infection in cells with an EC(50)…
High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2 - Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma (CP) or monoclonal antibodies (mAbs) in COVID-19 by targeting multiple antigen epitopes. However, heterologous antibodies trigger human natural xenogeneic antibody responses particularly directed against animal-type carbohydrates, mainly the N-glycolyl form of the neuraminic acid (Neu5Gc) and the Gal α1,3-galactose (αGal), potentially leading to serum sickness or allergy. Here, we immunized…
P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation - The global SARS-CoV-2 pandemic starting in 2019 has already reached more than 2.3 million deaths. Despite the scientific community’s efforts to investigate the COVID-19 disease, a drug for effectively treating or curing patients yet needs to be discovered. Hematopoietic stem cells (HSC) differentiating into immune cells for defense express COVID-19 entry receptors, and COVID-19 infection hinders their differentiation. The importance of purinergic signaling in HSC differentiation and innate…
Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVIrus Disease 2019 - Emerging evidence hints in favor of a life-threatening link between severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and the cardiovascular system. SARS-CoV-2 may result in dramatic cardiovascular complications, whereas the severity of COronaVIrus Disease 2019 (COVID-19) and the incidence of fatalities tend to increase in patients with pre-existing cardiovascular complications. SARS-CoV-2 is internalized into the host cells by endocytosis and may then escape the endolysosomal…
Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2 - An efficient treatment against a COVID-19 disease, caused by the novel coronavirus SARS-CoV-2 (CoV2), remains a challenge. The papain-like protease (PL^(pro)) from the human coronavirus is a protease that plays a critical role in virus replication. Moreover, CoV2 uses this enzyme to modulate the host’s immune system to its own benefit. Therefore, it represents a highly promising target for the development of antiviral drugs. We used Approximate Bayesian Computation tools, molecular modelling and…
Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses - The synthesis of α-fluorinated methyl ketones has always been challenging. New methods based on the homologation chemistry via nucleophilic halocarbenoid transfer, carried out recently in our labs, allowed us to design and synthesize a target-directed dipeptidyl α,α-difluoromethyl ketone (DFMK) 8 as a potential antiviral agent with activity against human coronaviruses. The ability of the newly synthesized compound to inhibit viral replication was evaluated by a viral cytopathic effect…
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the newly emergent causative agent of coronavirus disease-19 (COVID-19), has resulted in more than two million deaths worldwide since it was first detected in 2019. There is a critical global need for therapeutic intervention strategies that can be deployed to safely treat COVID-19 disease and reduce associated morbidity and mortality. Increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs), also…
Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics - Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has become a worldwide pandemic. Symptoms range from mild fever to cough, fatigue, severe pneumonia, acute respiratory distress syndrome (ARDS), and organ failure, with a mortality rate of 2.2%. However, there are no licensed drugs or definitive treatment strategies for patients with severe COVID-19. Only antiviral or anti-inflammatory drugs are used as symptomatic treatments based on clinician experience. Basic medical…
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro - An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy. Though the understanding of the disease has improved, fighting the virus remains challenging. One of the strategies is repurposing existing drugs as inhibitors of SARS-CoV-2. Fluoxetine (FLX), a selective serotonin reuptake inhibitor, reportedly inhibits the replication of RNA viruses, especially Coxsackieviruses B (CVB), such…
Compositions and methods for detecting SARS-CoV-2 spike protein - - link
SARS-CoV-2 antibodies - - link
SARS-CoV-2 antibodies - - link
病毒核酸提取或保存试剂、引物探针组合、病毒扩增试剂、试剂盒及其应用 - 本发明涉及病毒检测领域，特别涉及病毒核酸提取或保存试剂、引物探针组合、病毒扩增试剂、试剂盒及其应用。本发明病毒检测装置提供了一种简单易行的病毒核酸提取方法，整个过程大约5‑15分钟，回收纯化的核酸，可用于病毒核酸的检测。包括PCR、NASBA、LAMP、RPA等。相比较于传统的病毒提取方法，本方法病毒核酸回收率高、用时少、操作方便、易于临床推广。本发明涉及单管同时检测新型冠状病毒COVID‑19 N和ORF基因以及人源内参基因的等温扩增引物、探针组合序列和反应缓冲液，该体系特异性好，灵敏度高（50 cp/mL），特异性高，只需20 min的检测时间，最快可在10 min左右报阳性。 - link
一种侧链修饰的聚氨基酸及其制备方法和用途 - 本发明提供了一种侧链修饰的聚氨基酸及其制备方法，所述侧链修饰的聚氨基酸具有如下优势：（1）主链和侧链结构及其连接方式都可以灵活选取，使制得的聚合物胶束具有良好生物相容性和靶向递送效率，（2）聚氨基酸主链的电荷极性为电正性，对主链的电荷调节促进胶束的pH值响应，帮助RNA从“溶酶体陷阱”中逃离进入胞浆，（3）通过量化侧链修饰脂肪链的链长、饱和度和脂肪链数量来控制侧链的疏水性部分，精确调节疏水部分的体积和缔合作用强度，（4）由于RNA和DNA在结构和负电性上的相似性，高效构建包裹和递送体，（5）通过双亲性功能高分子的侧链修饰引入不同的生物功能基团，实现递送体系对靶点组织和部位的特异性结合，提高靶向递送效果。 - link
靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途 - 本发明涉及靶向SARS‑CoV‑2冠状病毒的抗体及其诊断和检测用途。具体涉及特异性结合冠状病毒S蛋白的抗体或其抗原结合片段和抗体对以及包含所述抗体或其抗原结合片段和抗体对的检测产品。本发明还涉及编码所述抗体或抗原结合片段的核酸及包含其的宿主细胞，以及制备所述抗体或抗原结合片段的方法。此外，本发明涉及所述抗体或其抗原结合片段、抗体对的预防、治疗或诊断用途。相较于常规的IgG/IgM检测，该检测方法直接检测样本中病毒的RBD蛋白，可以有效避免可能的样本中无关IgG/IgM对于检测的干扰，有效提高检测的灵敏度。所述抗体或抗体对可用于诊断和/或检测冠状病毒。 - link
A PHARMACEUTICAL COMPOSITION OF NITAZOXANIDE AND MEFLOQUINE AND METHOD THEREOF - A pharmaceutical composition for treating Covid-19 virus comprising a therapeutically effective amount of a nitazoxanide or its pharmaceutically acceptable salts thereof and an mefloquine or its pharmaceutically acceptable salts thereof is disclosed. The pharmaceutical composition comprises the nitazoxanide in the ratio of 0.05% to 66% w/v and the mefloquine in the ratio of 0.05% to 90% w/v. The composition is found to be effective for the treatment of COVID -19 (SARS-CoV2). The pharmaceutical composition of nitazoxanide and mefloquine has been found to be effective and is unexpectedly well tolerated with a low rate of side-effects, and equally high cure-rates than in comparable treatments. - link
TREATMENT OF COVID-19 WITH REBAMIPIDE - - link
METHOD AND APPARATUS FOR ACQUIRING POWER CONSUMPTION IMPACT BASED ON IMPACT OF COVID-19 EPIDEMIC - - link
一种新冠肺炎CT检测识别定位系统及计算设备 - 本发明涉及图像处理领域，公开了一种新冠肺炎CT检测识别定位系统及计算设备，包括图像采集单元、模块建立单元、新冠肺炎病灶识别单元和新冠肺炎病灶定位单元；图像采集单元采集待识别检测新冠肺炎的CT图像、新冠肺炎CT影像病灶分割训练数据集和新冠CT图像识别训练集；模块建立单元建立U_Net卷积神经网络模型、加入注意力机制的InceptionV3网络和目标检测模型；新冠肺炎病灶识别单元对已分割出病灶的轮廓特征图像进行识别；新冠肺炎病灶定位单元确定病灶在人体肺部的位置。本发明利用U_Net卷积神经网络模型对新冠病灶检测分割，并通过加入注意力机制的网络进行新冠肺炎识别，通过目标检测模型定位病灶在肺部的位置，识别准确率高，计算速度快。 - link